Skip to main content
SpringerLink
Log in

Clinical pharmacokinetics of vindesine

  • Original Articles
  • Vindesine Pharmacokinetics
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics of vindesine were investigated in five patients with advanced cancer who were receiving the drug. Following a rapid IV bolus dose, vindesine kinetics were described by a triphasic serum decay curve compatible with a three-compartment open mammillary model. Serum half-lives were 2 min, 50 min, and 24 h for the fast, middle, and slow phases, respectively. The volume of the central compartment approximated the plasma volume in all patients studied. Distribution occurred quickly into a superficial tissue compartment in fairly rapid equilibrium with the plasma compartment, and also into a deep tissue compartment with slower redistribution to the central compartment. The large apparent volume of distribution and long elimination half-live suggest extensive tissue sequestration or delayed excretion of the drug in man. The slightly increased serum half-life of vindesine compared with published results for vinblastine may account for the greater degree and longer duration of marrow suppression seen clinically with vindesine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bodey, G. P., Freireich, E. J.: Initial clinical studies of vindesine (desacetyl vinblastine amide sulfate). Proc. Am. Assoc. Cancer Res. and Am. Soc. Clin. Oncol. 17, 128 (1976)

    Google Scholar 

  2. Culp, H. W., Daniels, W. D., McMahon, R. E.: Disposition and tissue levels of[3H]-vindesine in rats. Cancer Res. 37, 3035–56 (1977)

    Google Scholar 

  3. Dyke, R. W., Nelson, R. L.: Phase I anti-cancer agents. Vindesine (desacetyl vinblastine amide sulfate). Cancer Treat. Rev. 4, 135–142 (1977)

    Google Scholar 

  4. Dyke, R. W., Nelson, R. L.: Phase I-II clinical investigation of vindesine (desacetyl vinblastine amide sulfate, DVA). In: Tenth International Congress of Chemotherapy, Zurich, Switzerland, September 1977, Abst. 640.

  5. Knott, G. D., Reece, D. K.: MLAB: A civilized curve fitting system. In: Proceedings of the ONLINE 1972 International Conference, Brunel University, England, Vol. 1, pp. 497–526.

  6. Krivit, W., Hammond, D.: Vindesine: a phase II study by the Children's Cancer Study Group. In: Current chemotherapy, Vol. II, pp. 1331–1334. Washington, DC: American Society for Microbiology 1978

    Google Scholar 

  7. Loeb, E., Hill, J. M., Pardue, A. S., et al.: Vindesine, a new vinca alkaloid in the treatment of leukemia and lymphoma. In: Current chemotherapy, Vol. II, pp. 1334–1336. Washington, DC: American Society for Microbiology 1978

    Google Scholar 

  8. Mathé, G., Misset, J. L., Vassal, F. de, et al.: Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and Hodgkin's disease: Absence of cross-resistance with vincristine. Cancer Treat. Rep. 62, 805–809 (1978)

    Google Scholar 

  9. Nelson, R. L., Dyke, R. W.: Phase I-II clinical investigation of vindesine (desacetyl vinblastine amide sulfate). In: Current chemotherapy, Vol. II, pp. 1328–1329. Washington, DC: American Society for Microbiology 1978

    Google Scholar 

  10. Owellen, R. J., Hartke, C. A., Hains, F. O.: Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res. 37, 2597–2602 (1977)

    Google Scholar 

  11. Owellen, R. J., Root, M. A., Hains, F. O.: Pharmacokinetics of vindesine and vincristine in humans. Cancer Res. 37, 2603-to2607 (1977)

    Google Scholar 

  12. Root, M. A., Gerzon, K., Dyke, R. W.: A radioimmunoassay for vinblastine and vincristine. Federation of Analytical Chemistry and Spectroscopy Societies, October 1975, Indianapolis, Indiana, pg. 125.

    Google Scholar 

  13. Sweeney, M. J., Cullinan, G. J., Poore, G. A., et al.: Experimental antitumor activity of vinblastine amides. Proc. Am. Assoc. Cancer Res. and Am. Soc. Clin. Oncol. 15, 146A (1974)

  14. Tan, C.: Vindesine. Clinical and pharmacokinetic studies of vindesine in 50 children with malignant diseases. In: Current chemotherapy, Vol. II, pp. 1326–28. Washington, DC: American Society for Microbiology 1978

    Google Scholar 

  15. Todd, G. C., Gibson, W. R., Morton, D. M.: Toxicology of vindesine (desacetyl vinblastine amide) in mice, rats, and dogs. J. Toxicol. Environ. Health 1, 843–50 (1976)

    Google Scholar 

  16. Wagner, J. G.: Fundamentals of clinical pharmacokinetics, pp. 114–117. Hamilton, Ill.: Drug Intelligence Publications 1975

    Google Scholar 

  17. Young, C. W., Currie, V., Cvitkovic, E., et al.: Early phase II evaluation of vindesine in patients with advanced cancer. In: Current chemotherapy, Vol. II, pp. 1330–1331 Washington, DC: American Society for Microbiology 1978

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Lilly Laboratory for Clinical Research, Wishard Memorial Hospital, 46202, Indianapolis, Indiana, USA

    R. L. Nelson & R. W. Dyke

  2. School of Medicine, Wishard Memorial Hospital, Indiana University, 46202, Indianapolis, Indiana, USA

    R. L. Nelson & R. W. Dyke

  3. Eli Lilly and Company, 46206, Indianapolis, Indiana, USA

    M. A. Root

Authors
  1. R. L. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. W. Dyke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. A. Root
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nelson, R.L., Dyke, R.W. & Root, M.A. Clinical pharmacokinetics of vindesine. Cancer Chemother. Pharmacol. 2, 243–246 (1979). https://doi.org/10.1007/BF00257188

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257188

Keywords

Search

Navigation